Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Variegate Porphyria Workup

  • Author: Maureen B Poh-Fitzpatrick, MD; Chief Editor: Dirk M Elston, MD  more...
 
Updated: Apr 15, 2016
 

Laboratory Studies

Urinary aminolevulinic acid and porphobilinogen levels are greatly elevated during attacks but often normalize during quiescent phases.[23] Older urinary porphobilinogen screening assays (eg, Watson-Schwartz and Hoesch methods)[24] have largely been supplanted by a commercial test kit that provides rapid, specific semiquantitative urinary porphobilinogen estimation (PBG Kit, Thermo Fisher Scientific; Waltham, Mass). Because medical management of an attack is the same for all acute porphyrias, screening evidence of elevated porphobilinogen is sufficient to justify initiating therapies in crisis situations, before quantitative laboratory data for porphyrins and porphyrin precursors that establish a precise diagnosis become available. Progressive motor weakness due to porphyric neuropathy, typically accompanied by high urinary porphobilinogen but normal cerebrospinal fluid protein levels, can be differentiated from acute ascending polyneuropathy (Landry-Guillain-Barré syndrome) by the normal urinary porphobilinogen but increased cerebrospinal fluid protein levels typical of the latter disorder.[25]

During symptomatic phases of variegate porphyria, urinary porphyrin levels are abnormally high, with coproporphyrin greater than uroporphyrin. Total fecal porphyrin excretion is also high; both protoporphyrin and coproporphyrin fractions are elevated,[26] with protoporphyrin greater than or equal to coproporphyrin. The isomer ratio of coproporphyrin III to coproporphyrin I is several-fold higher than normal.[27]

Erythrocyte porphyrin levels are typically normal in patients with one normal allele for the protoporphyrin oxidase gene and one with a deleterious mutation, but when 2 mutant alleles are present, zinc-protoporphyrin is elevated.[4, 16, 21]

Plasma porphyrin levels are increased in symptomatic patients. A fluorescence emission peak maximal at 625-627 nm detected by spectrofluorometry is unique to variegate porphyria, enabling rapid diagnostic confirmation.[28] Spectrofluorometry detects such plasma porphyrin peaks in many, but not all, asymptomatic adult carriers of protoporphyrin oxidase gene mutations, but only in some prepubertal carriers.[26]

Porphyrin abnormalities in urine, stool, and plasma may normalize during quiescent phases, or remain increased at variable levels. Increased biliary porphyrin levels may be the most sensitive biochemical indicator during quiescence.[29]

Assays for protoporphyrinogen oxidase enzyme activity are technically difficult, but are available in specialized porphyria laboratories in several countries.

Mutation analysis of the protoporphyrinogen oxidase gene is performed in several centers with particular interest in porphyrias and is commercially available in the United States. Because variegate porphyria in most individuals carrying a mutated gene remains clinically silent and may also be biochemically silent, family studies aimed at identifying all adults and children at risk for developing variegate porphyria require mutation analysis for absolute certainty of identifying all carriers.

Next

Imaging Studies

Ultrasonography screening for hepatocellular carcinoma is indicated at least annually for individuals with variegate porphyria aged 50 years or older, especially those who have had long-term elevations of porphyrins and porphobilinogen. Gallstones may also be detected by ultrasonography.

Bone mineral density scanning can be performed to detect significant bone loss in individuals who have avoided sunlight over long periods because of unremitting porphyric photosensitivity.

Previous
Next

Other Tests

Serum vitamin D levels are recommended to assess insufficient or deficient levels resulting from long-term avoidance of sunlight exposure.

Periodic serum α-fetoprotein assessment is useful in surveillance for the development of hepatocellular carcinoma.

Periodic assessment of renal function is indicated in individuals with chronic arterial hypertension.

Previous
Next

Histologic Findings

Histologic findings resembling those of porphyria cutanea tarda are well described.[30, 31] Bullae are subepidermal and cell poor; a mild perivascular lymphocytic inflammatory infiltrate may be present. Thickened, hyalinized superficial dermal blood vessel walls contain periodic acid-Schiff stain–positive, diastase-resistant glycoprotein deposits. Ultrastructural examination of the dermal vasculature and the dermoepidermal junction reveals replicated basement membranes believed to be elaborated by multiple episodes of damage and repair and fine fibrillar material in the surrounding dermis. Immunoglobulin and complement deposits that are present perivascularly and at the dermoepidermal junction are believed to be due to leakage of these proteins from damaged blood vessels rather than to immunologically mediated events.

Previous
 
 
Contributor Information and Disclosures
Author

Maureen B Poh-Fitzpatrick, MD Professor Emerita of Dermatology and Special Lecturer, Columbia University College of Physicians and Surgeons

Maureen B Poh-Fitzpatrick, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, New York Academy of Medicine, New York Dermatological Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Julia R Nunley, MD Professor, Program Director, Dermatology Residency, Department of Dermatology, Virginia Commonwealth University Medical Center

Julia R Nunley, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Society of Nephrology, International Society of Nephrology, Medical Dermatology Society, Medical Society of Virginia, National Kidney Foundation, Phi Beta Kappa, Women's Dermatologic Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: American Board of Dermatology<br/>Co-Editor for the text Dermatological Manifestations of Kidney Disease .

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

David Timothy Woodley, MD Professor and Chair, Department of Dermatology, Keck School of Medicine of the University of Southern California

David Timothy Woodley, MD is a member of the following medical societies: American Academy of Dermatology, American Association for the Advancement of Science, American College of Emergency Physicians, American College of Physicians, American Federation for Medical Research, American Society for Clinical Investigation, New York Academy of Medicine, Society for Investigative Dermatology, Southern Medical Association

Disclosure: Received consulting fee from Shire Pharmaceuticals for consulting.

References
  1. Brenner DA, Bloomer JR. The enzymatic defect in variegate prophyria. Studies with human cultured skin fibroblasts. N Engl J Med. 1980 Apr 3. 302(14):765-9. [Medline].

  2. Meissner PN, Day RS, Moore MR, Disler PB, Harley E. Protoporphyrinogen oxidase and porphobilinogen deaminase in variegate porphyria. Eur J Clin Invest. 1986 Jun. 16(3):257-61. [Medline].

  3. Kirsch RE, Meissner PN, Hift RJ. Variegate porphyria. Semin Liver Dis. 1998. 18(1):33-41. [Medline].

  4. Whatley SD, Puy H, Morgan RR, et al. Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am J Hum Genet. 1999 Oct. 65(4):984-94. [Medline].

  5. Eales L, Day RS, Blekkenhorst GH. The clinical and biochemical features of variegate porphyria: an analysis of 300 cases studied at Groote Schuur Hospital, Cape Town. Int J Biochem. 1980. 12(5-6):837-53. [Medline].

  6. Mustajoki P. Variegate porphyria. Twelve years' experience in Finland. Q J Med. 1980 Spring. 49(194):191-203. [Medline].

  7. Bonkowsky HL, Schady W. Neurologic manifestations of acute porphyria. Semin Liver Dis. 1982 May. 2(2):108-24. [Medline].

  8. Bonkovsky HL, Barnard GF. The Porphyrias. Curr Treat Options Gastroenterol. 2000 Dec. 3(6):487-500. [Medline].

  9. Meissner P, Adams P, Kirsch R. Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria. J Clin Invest. 1993 Apr. 91(4):1436-44. [Medline].

  10. Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis. 1998. 18(1):43-52. [Medline].

  11. Dean G. The porphyrias. A story of inheritance and environment. London: Pitman Medical; 1971. 2nd ed.

  12. Meissner PN, Dailey TA, Hift RJ, Ziman M, Corrigall AV, Roberts AG. A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet. 1996 May. 13(1):95-7. [Medline].

  13. van Serooskerken AM, Ernst M, Bladergroen RS, Wolff C, Floderus Y, Harper P. A recurrent mutation in variegate porphyria patients from Chile and Sweden: Evidence for a common genetic background?. J Dermatol Sci. 2011 Jan. 61(1):75-7. [Medline].

  14. Frank J, Alta VM, Ahmad W, Lam H, Wolff C, Christiano AM. Identification of a Founder Mutation in the Protoporphyrinogen Oxidase Gene in Variegate Porphyria Patients from Chile. Human Heredity. 2001. 51:160-8.

  15. Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2012 Nov 1. [Medline].

  16. Mustajoki P, Tenhunen R, Niemi KM, Nordmann Y, Kaariainen H, Norio R. Homozygous variegate porphyria. A severe skin disease of infancy. Clin Genet. 1987 Nov. 32(5):300-5. [Medline].

  17. Corrigall AV, Hift RJ, Davids LM, et al. Homozygous variegate porphyria in South Africa: genotypic analysis in two cases. Mol Genet Metab. 2000 Apr. 69(4):323-30. [Medline].

  18. Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore). 2005 Jan. 84(1):48-60. [Medline].

  19. von und zu Fraunberg M, Timonen K, Mustajoki P, Kauppinen R. Clinical and biochemical characteristics and genotype-phenotype correlation in Finnish variegate porphyria patients. Eur J Hum Genet. 2002 Oct. 10(10):649-57. [Medline].

  20. Hift RJ, Meissner D, Meissner PN. A systematic study of the clinical and biochemical expression of variegate porphyria in a large South African family. Br J Dermatol. 2004 Aug. 151(2):465-71. [Medline].

  21. Korda V, Deybach JC, Martasek P, et al. Homozygous variegate porphyria. Lancet. 1984 Apr 14. 1(8381):851. [Medline].

  22. Hift RJ, Meissner PN, Todd G, et al. Homozygous variegate porphyria: an evolving clinical syndrome. Postgrad Med J. 1993 Oct. 69(816):781-6. [Medline].

  23. Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol. 2006 Nov. 135(3):281-92. [Medline].

  24. Zaider E, Bickers DR. Clinical laboratory methods for diagnosis of the porphyrias. Clin Dermatol. 1998 Mar-Apr. 16(2):277-93. [Medline].

  25. Singal AK, Anderson KE. Variegate porphyria. GeneReviews - NCBI Bookshelf. Feb 14, 2013. [Medline]. [Full Text].

  26. Hift RJ, Davidson BP, van der Hooft C, Meissner DM, Meissner PN. Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard. Clin Chem. 2004 May. 50(5):915-23. [Medline].

  27. Kühnel A, Gross U, Jacob K, Doss MO. Studies on coproporphyrin isomers in urine and feces in the porphyrias. Clin Chim Acta. 1999 Apr. 282 (1-2):45-58. [Medline].

  28. Poh-Fitzpatrick MB. A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol. 1980 May. 116(5):543-7. [Medline].

  29. Logan GM, Weimer MK, Ellefson M, Pierach CA, Bloomer JR. Bile porphyrin analysis in the evaluation of variegate porphyria. N Engl J Med. 1991 May 16. 324(20):1408-11. [Medline].

  30. Epstein JH, Tuffanelli DL, Epstein WL. Cutaneous changes in the porphyrias. A microscopic study. Arch Dermatol. 1973 May. 107(5):689-98. [Medline].

  31. Timonen K, Niemi KM, Mustajoki P, Tenhunen R. Skin changes in variegate porphyria. Clinical, histopathological, and ultrastructural study. Arch Dermatol Res. 1990. 282(2):108-14. [Medline].

  32. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005 Mar 15. 142(6):439-50. [Medline].

  33. Kalman DR, Bonkovsky HL. Management of acute attacks in the porphyrias. Clin Dermatol. 1998 Mar-Apr. 16(2):299-306. [Medline].

  34. Findley H, Philips A, Cole D, Nair A. Porphyrias: implications for anaesthesia, critical care, and pain medicine. Oxford Journals. Available at http://ceaccp.oxfordjournals.org/content/early/2012/02/27/bjaceaccp.mks009.full. February 27, 2012; Accessed: April 8, 2016.

  35. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015. 8:201-14. [Medline].

  36. Tschudy DP, Welland FH, Collins A, Hunter G Jr. The effect of carbohydrate feeding on the induction of delta-aminolevulinic acid synthatase. Metabolism. 1964 May. 13:396-406. [Medline].

  37. Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol. 1991 Aug. 86(8):1050-6. [Medline].

  38. Anderson KE, Spitz IM, Sassa S, Bardin CW, Kappas A. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med. 1984 Sep 6. 311(10):643-5. [Medline].

  39. Stojeba N, Meyer C, Jeanpierre C, et al. Recovery from a variegate porphyria by a liver transplantation. Liver Transpl. 2004 Jul. 10(7):935-8. [Medline].

  40. Church SE, McColl KE, Moore MR, Youngs GR. Hypertension and renal impairment as complications of acute porphyria. Nephrol Dial Transplant. 1992. 7 (10):986-90. [Medline].

  41. Schneider-Yin X, van Tuyll van Serooskerken AM, Went P, Tyblewski W, Poblete-Gutiérrez P, Minder EI. Hepatocellular carcinoma in variegate porphyria: a serious complication. Acta Derm Venereol. 2010 Sep. 90(5):512-5. [Medline].

  42. Luvai A, Mbagaya W, Narayanan D, Degg T, Toogood G, Wyatt JI, et al. Hepatocellular carcinoma in variegate porphyria: a case report and literature review. Ann Clin Biochem. 2015 May. 52 (Pt 3):407-12. [Medline].

  43. Herrick AL, Moore MR, Thompson GG, Ford GP, McColl KE. Cholelithiasis in patients with variegate porphyria. J Hepatol. 1991 Jan. 12 (1):50-3. [Medline].

  44. Muraldihar A, Vikram RS, Pechtor K, Howell MR. Recurrent variegate porphyria in a pregnant woman. Journal of Obstetrics and Gynaecology. 2006. 8:809-824.

  45. Wolff C, Merino RA. Porfiria y embarazo. Rev Med Chile. 2008. 136:151-156.

  46. Marsden JT, Rees DC. A retrospective analysis of outcome of pregnancy in patients with acute porphyria. J Inherit Metab Dis. 2010 Oct. 33(5):591-6. [Medline].

  47. Badminton MN, Deybach JC. Treatment of an acute attack of porphyria during pregnancy. Eur J Neurol. 2006 Jun. 13 (6):668-9. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.